Weekly Treatment with SAMiRNA Targeting the Androgen Receptor Ameliorates Androgenetic Alopecia
January 2022
in “
Scientific Reports
”
Studysummary This study found that SAMiRNA-AR68, a nanomedicine targeting androgen receptor mRNA, increased hair counts in androgenetic alopecia patients with no observed side effects.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on nature.com →